Drugmaker Sandoz will pay $195 million as part of a deferred prosecution agreement it struck with the US Department of Justice to resolve criminal charges for its role in several conspiracies to drive up the price of generic drugs. A DPA was used to avoid barring Sandoz from participation in federal health